Arcellx Inc (ACLX)
54.41
-0.31
(-0.57%)
USD |
NASDAQ |
Jul 05, 15:04
Arcellx SG&A Expense (TTM): 73.66M for March 31, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 73.66M |
December 31, 2023 | 66.35M |
September 30, 2023 | 61.04M |
June 30, 2023 | 55.44M |
March 31, 2023 | 49.11M |
December 31, 2022 | 41.70M |
Date | Value |
---|---|
September 30, 2022 | 34.95M |
June 30, 2022 | 29.33M |
March 31, 2022 | 23.41M |
December 31, 2021 | 18.14M |
September 30, 2021 | 13.00M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
13.00M
Minimum
Sep 2021
73.66M
Maximum
Mar 2024
42.37M
Average
41.70M
Median
Dec 2022
SG&A Expense (TTM) Benchmarks
BridgeBio Pharma Inc | 185.29M |
Gilead Sciences Inc | 6.147B |
Agios Pharmaceuticals Inc | 122.55M |
Krystal Biotech Inc | 100.42M |
Arvinas Inc | 99.60M |